5% Off
Gazyva1000 mg/40
Roche Bangladesh Ltd.
৳106400.00
Out Of Stock
Generic medicine
Obinutuzumab: Brands, Price & Uses in Bangladesh
Obinutuzumab is a humanized, glycoengineered type II anti-CD20 monoclonal antibody administered by intravenous infusion under the supervision of a physician experienced in the use of…
About Obinutuzumab
Indications of Obinutuzumab
Obinutuzumab is a humanized, glycoengineered type II anti-CD20 monoclonal antibody administered by intravenous infusion under the supervision of a physician experienced in the use of anticancer/biologic therapy. Approved (established) indications include:
- Chronic lymphocytic leukemia (CLL), previously untreated (FDA-approved, combination therapy required): Obinutuzumab, in combination with chlorambucil, is indicated for the treatment of adults with previously untreated CLL.
- Follicular lymphoma (FL), previously untreated (FDA-approved, combination therapy required): Obinutuzumab, in combination with chemotherapy followed by Obinutuzumab maintenance in responders, is indicated for the first-line treatment of adults with stage II bulky, III, or IV follicular lymphoma.
- Follicular lymphoma, relapsed/refractory (FDA-approved, combination therapy required): Obinutuzumab, in combination with bendamustine followed by Obinutuzumab maintenance, is indicated for adults with follicular lymphoma who did not respond to, or who progressed during or within 6 months of completion of, a rituximab-containing regimen.
Obinutuzumab is always given as part of a combination or maintenance regimen for these indications; it is not used as standalone first-line therapy without a partner chemotherapy agent. Use outside these approved settings (e.g. other B-cell malignancies) is considered off-label and should only be undertaken by a specialist based on clinical judgment and emerging evidence.
Dosage & Administration of Obinutuzumab
Obinutuzumab is given only by intravenous infusion, after dilution, in a facility with resuscitation equipment and personnel trained to manage severe infusion and hypersensitivity reactions. Premedication is mandatory before every infusion (see Administration). Dosing is structured per indication and per infusion within each cycle (28-day cycles):
| Indication | Cycle 1 (Days) | Cycles 2 onward | Notes |
|---|---|---|---|
| Previously untreated CLL (with chlorambucil) | Day 1: 100 mg; Day 2: 900 mg; Day 8: 1000 mg; Day 15: 1000 mg | Day 1: 1000 mg (Cycles 2-6) | Total 6 cycles |
| Previously untreated follicular lymphoma (with chemotherapy) | Day 1: 1000 mg (may be split over Days 1-2); Day 8: 1000 mg; Day 15: 1000 mg | Day 1: 1000 mg (Cycles 2-6 or 2-8, per chemotherapy backbone) | Followed by Obinutuzumab maintenance 1000 mg every 2 months for up to 2 years in responders |
| Relapsed/refractory follicular lymphoma (with bendamustine) | Day 1: 1000 mg (may be split over Days 1-2); Day 8: 1000 mg; Day 15: 1000 mg | Day 1: 1000 mg (Cycles 2-6) | Followed by Obinutuzumab maintenance 1000 mg every 2 months for up to 2 years or until disease progression |
The infusion rate is started slowly and increased gradually only if no infusion reaction occurs; the first infusion in particular is given over several hours with close monitoring. Doses missed or delayed due to toxicity should be managed per institutional oncology protocol and physician judgment, not self-adjusted.
Side Effects of Obinutuzumab
The most common adverse reactions reported with Obinutuzumab (occurring in a substantial proportion of patients) include:
- Infusion-related reactions (very common, can be severe - see Precautions and Warnings)
- Neutropenia and thrombocytopenia (common; monitor blood counts)
- Infections, including upper respiratory tract infections
- Cough
- Musculoskeletal disorders (arthralgia, back pain)
- Diarrhea and constipation
- Fatigue and fever
Less common but serious adverse effects include tumor lysis syndrome, hepatitis B reactivation, progressive multifocal leukoencephalopathy, and severe or fatal infusion reactions (see Precautions and Warnings for full detail). Patients should promptly report fever, signs of infection, unusual bleeding or bruising, or any reaction occurring during or shortly after an infusion.
Contraindications of Obinutuzumab
Obinutuzumab is contraindicated in patients with known severe hypersensitivity to Obinutuzumab or to any component of the formulation. There is no other well-established absolute contraindication; however, active hepatitis B virus infection should be excluded before starting Obinutuzumab because of the risk of fatal reactivation (see Precautions and Warnings), and use should not proceed in patients with active, uncontrolled hepatitis B infection until this has been addressed with a hepatologist/infectious disease specialist.
Frequently Asked Questions about Obinutuzumab
What is Obinutuzumab used for?
Obinutuzumab is a targeted biologic medicine (a monoclonal antibody) used, in combination with other chemotherapy medicines, to treat certain B-cell blood cancers - specifically chronic lymphocytic leukemia (CLL) and follicular lymphoma - under the care of a cancer specialist.
How is Obinutuzumab given?
Obinutuzumab is given only as a slow intravenous infusion in a hospital or clinic by trained healthcare staff, after you have received premedication (a steroid, an antihistamine, and paracetamol) to reduce the risk of infusion reactions. It cannot be taken as a tablet or given at home.
What are the most serious risks of Obinutuzumab?
Obinutuzumab carries boxed warnings for reactivation of hepatitis B virus infection (which can be life-threatening, so you will be screened for hepatitis B before starting) and for severe, sometimes fatal, infusion-related reactions (which is why premedication and close monitoring during infusions are required). Other serious risks include a rare brain infection called PML, tumor lysis syndrome, and low blood cell counts.
Can Obinutuzumab be used during pregnancy or breastfeeding?
Obinutuzumab should be used in pregnancy only if clearly needed and the potential benefit justifies the potential risk to the baby, since it can cross the placenta and affect the baby's B cells; effective contraception is recommended during treatment and for 18 months after the last dose. Breastfeeding should only be resumed or continued after discussion with your physician, weighing the importance of treatment against potential risk to the infant.
What side effects should I watch for with Obinutuzumab?
Common effects include reactions during or shortly after the infusion (fever, chills, low blood pressure, breathing difficulty), low white blood cell and platelet counts, infections, cough, and joint or back pain. Report fever, signs of infection, unusual bleeding, or any reaction during an infusion to your medical team immediately.
What if a dose of Obinutuzumab is missed or an overdose is suspected?
Obinutuzumab is administered in a clinical setting on a schedule set by your oncology team, so a missed dose should be rescheduled with them as soon as possible. If an overdose or infusion problem is suspected, it will be managed immediately by the treating medical staff; if you have concerns after leaving the facility, seek immediate medical attention or contact emergency services.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.